We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Pathward Financial
CASH
$1.82B
| $479K | ﹤0.01% |
12,376
-2,906
| -19% | -$124K |
|
1702
Zevra Therapeutics
ZVRA
$678M
| $479K | ﹤0.01% |
107,341
-102,759
| -49% | -$468K |
|
|
VIVO
1703
DELISTED
Meridian Bioscience Inc
VIVO
| $478K | ﹤0.01% |
15,722
+4,100
| +35% | +$111K |
|
|
GOOD
1704
Gladstone Commercial Corp
GOOD
$623M
| $476K | ﹤0.01% |
25,276
+8,120
| +47% | +$165K |
|
1705
Dine Brands
DIN
$454M
| $475K | ﹤0.01% |
7,296
-6,507
| -47% | -$465K |
|
|
LTHM
1706
DELISTED
Livent Corporation
LTHM
| $472K | ﹤0.01% |
20,799
-2,081
| -9% | -$53.6K |
|
1707
Tiptree Inc
TIPT
$676M
| $470K | ﹤0.01% |
44,240
-18,791
| -30% | -$211K |
|
1708
Carriage Services
CSV
$543M
| $467K | ﹤0.01% |
11,788
+1,561
| +15% | +$67.4K |
|
|
FIRY
1709
Firy Inc
FIRY
$159M
| $464K | ﹤0.01% |
19,934
+16,523
| +484% | +$645K |
|
1710
Vishay Precision Group
VPG
$878M
| $464K | ﹤0.01% |
15,944
-3,006
| -16% | -$92K |
|
1711
Utah Medical Products
UTMD
$230M
| $459K | ﹤0.01% |
5,346
+2,218
| +71% | +$189K |
|
1712
Lindsay Corp
LNN
$1.18B
| $457K | ﹤0.01% |
3,441
-2,957
| -46% | -$392K |
|
|
AAMI
1713
Acadian Asset Management
AAMI
$3.24B
| $457K | ﹤0.01% |
25,372
-10,650
| -30% | -$218K |
|
1714
Peoples Bancorp
PEBO
$1.47B
| $453K | ﹤0.01% |
17,012
+6,542
| +62% | +$186K |
|
|
SNBR
1715
DELISTED
Sleep Number
SNBR
| $452K | ﹤0.01% |
14,603
+5,432
| +59% | +$231K |
|
1716
Shutterstock
SSTK
$208M
| $452K | ﹤0.01% |
7,894
-17,650
| -69% | -$1.18M |
|
|
CTT
1717
DELISTED
CATCHMARK TIMBER TRUST, INC.
CTT
| $452K | ﹤0.01% |
44,975
-16,806
| -27% | -$154K |
|
1718
Vera Bradley
VRA
$94.4M
| $451K | ﹤0.01% |
103,929
+38,161
| +58% | +$233K |
|
|
PLYM
1719
DELISTED
Plymouth Industrial REIT
PLYM
| $450K | ﹤0.01% |
25,652
+5,730
| +29% | +$124K |
|
|
SAFE
1720
DELISTED
Safehold Inc.
SAFE
| $444K | ﹤0.01% |
12,546
+344
| +3% | +$15K |
|
1721
Brady Corp
BRC
$4.52B
| $440K | ﹤0.01% |
9,322
-2,829
| -23% | -$130K |
|
1722
Cabot Corp
CBT
$4.52B
| $440K | ﹤0.01% |
7,067
-1,993
| -22% | -$136K |
|
1723
Green Brick Partners
GRBK
$3.08B
| $439K | ﹤0.01% |
22,433
-4,261
| -16% | -$89.4K |
|
1724
Radiant Logistics
RLGT
$386M
| $439K | ﹤0.01% |
59,132
-122,967
| -68% | -$790K |
|
1725
Xencor
XNCR
$1.63B
| $438K | ﹤0.01% |
15,994
+5,332
| +50% | +$132K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.